Madrigal Pharmaceuticals Announces Additions to Its Leadership Team
January 29 2024 - 7:00AM
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage
biopharmaceutical company pursuing novel therapeutics for
nonalcoholic steatohepatitis (NASH), today announced three new
members of its leadership team: Mark Barrett joins Madrigal as
Chief Business Officer, Clint Wallace joins as Chief Human
Resources Officer and Tina Ventura joins as Chief Investor
Relations Officer.
“I am delighted to welcome Mark, Clint and Tina to the team,”
said Bill Sibold, Chief Executive Officer of Madrigal. “As we
prepare for a first-to-market launch of resmetirom in NASH with
significant fibrosis, we are also building a foundation for
enduring leadership. These new leaders are not only experts in
their respective areas but have experience scaling teams and
organizations. They will each play a pivotal role in Madrigal’s
next phase of growth.”
Mark Barrett brings more than 25 years of biopharmaceutical
leadership and industry experience to Madrigal, with a track record
of success completing a wide range of partnerships and acquisitions
to build commercial portfolios and R&D pipelines across
therapeutic areas. He was most recently co-founder, Director, and
CEO of Lassen Therapeutics, a biotechnology company focused on
discovery and development of novel antibody therapeutics in
immunological diseases and cancer. Mr. Barrett has also served as
Entrepreneur in Residence at Frazier Healthcare Partners, where he
focused on starting and financing new biotech companies. Prior to
Lassen, he held leadership positions in Strategy and Business
Development at Johnson & Johnson and Sanofi. He holds an M.B.A
from the University of California at Berkeley and a B.S. degree in
Biology from Duke University.
Clint Wallace joins Madrigal from Kenvue, where he served as
Senior Vice President Human Resources, Global Functions and
Organizations and was responsible for organizational design and
talent succession strategy. Prior to Kenvue, he was the Senior Vice
President Human Resources, North America, Sanofi, from 2016-2022,
serving as a member of the Sanofi Global HR Leadership Team. Prior
to Sanofi, Mr. Wallace served in HR leadership positions at BASF
Corporation, GE Healthcare and Pratt & Whitney. He was a
Commissioned Officer in the U.S. Air Force and retired in June 2008
after 21 years of service. He holds an M.B.A. from Rensselaer
Polytechnic Institute and a B.S. degree in Manufacturing
Engineering from Central Connecticut State University.
Tina Ventura brings nearly 25 years of experience in global
health care investor relations and communications to Madrigal.
Before joining Madrigal, she was Chief Investor Relations Officer
at Horizon Therapeutics (acquired by Amgen) where she led the
company's investor relations efforts to shape its investment
identity as a rare disease-focused biotech, build and develop its
investor base and drive shareholder value creation. Prior to
Horizon, Ventura was Divisional Vice President, Investor Relations,
Abbott, spending 16 years at the diversified healthcare company in
positions of increasing responsibility in communications and
investor relations. She has been ranked a number-one IR
professional by Institutional Investor. Ventura holds an M.B.A.
from Loyola University and a B.A. degree in Communications from
Northwestern University.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a
clinical-stage biopharmaceutical company pursuing novel
therapeutics for nonalcoholic steatohepatitis (NASH), a liver
disease with high unmet medical need. Madrigal’s lead candidate,
resmetirom, is a liver-directed THR-β agonist oral therapy that is
designed to target key underlying causes of NASH. For more
information, visit www.madrigalpharma.com.
Investor Contact Tina Ventura, Madrigal
Pharmaceuticals, Inc., IR@madrigalpharma.com
Media ContactChristopher Frates, Madrigal
Pharmaceuticals, Inc., media@madrigalpharma.com
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
From May 2024 to Jun 2024
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
From Jun 2023 to Jun 2024